Molecular Partners Ag (MOLN) Shares Outstanding (2020 - 2026)
Molecular Partners Ag (MOLN) posted quarterly Shares Outstanding (Entity) of $40.4 million for Q4 2025, little changed year-over-year from $40.4 million in Q4 2024, and little changed quarter-over-quarter from $40.4 million in Q2 2025.
Molecular Partners Ag (MOLN) Shares Outstanding (2020 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Shares Outstanding (Entity) for 6 consecutive years, with $40.4 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Shares Outstanding (Entity) changed 0.03% year-over-year to $40.4 million; the TTM figure through Dec 2025 stood at $40.4 million (changed 0.03% YoY), while the FY2025 annual figure was $40.4 million, changed 0.03% from the prior year.
- Shares Outstanding (Entity) was little changed at $40.4 million in Q4 2025 per MOLN's latest filing, from $40.4 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $40.4 million in Q2 2025 and bottomed at $29.7 million in Q2 2021.
- Historically, Shares Outstanding (Entity) has averaged $36.1 million across 5 years, with a median of $36.3 million in 2023.
- Annual changes were most pronounced in 2023 — Shares Outstanding (Entity) grew 11.78% — and 2025, when it advanced 0.03%.
- Molecular Partners Ag's Shares Outstanding (Entity) stood at $32.3 million in 2021, then climbed by 11.62% to $36.0 million in 2022, then advanced by 0.86% to $36.4 million in 2023, then rose by 11.03% to $40.4 million in 2024, then climbed by 0.03% to $40.4 million in 2025.
- Business Quant data shows MOLN's Shares Outstanding (Entity) at $40.4 million in Q4 2025, $40.4 million in Q2 2025, and $40.4 million in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.76 Bn | 131.91 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 86.51 Bn | 78.51 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 65.74 Bn | 60.56 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 59.39 Bn | 54.26 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 42.24 Bn | 37.15 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.78 Bn | 28.47 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.65 Bn | 10.26 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.22 Bn | 26.39 Bn | - | 445.06 Mn |
| 10 | Molecular Partners Ag | 163.25 Mn | 163.25 Mn | - | 37.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 37.27 Mn |
| Dec 31, 2025 | 37.27 Mn |
| Sep 30, 2025 | 37.39 Mn |
| Jun 30, 2025 | 37.39 Mn |
| Mar 31, 2025 | 34.03 Mn |
| Dec 31, 2024 | 34.03 Mn |
| Sep 30, 2024 | 33.18 Mn |
| Jun 30, 2024 | 33.18 Mn |
| Mar 31, 2024 | 32.77 Mn |
| Dec 31, 2023 | 32.77 Mn |
| Sep 30, 2023 | 32.83 Mn |
| Jun 30, 2023 | 32.83 Mn |
| Mar 31, 2023 | 32.47 Mn |
| Dec 31, 2022 | 32.47 Mn |
| Sep 30, 2022 | 32.50 Mn |
| Jun 30, 2022 | 32.50 Mn |
| Mar 31, 2022 | 31.01 Mn |
| Dec 31, 2021 | 31.01 Mn |
| Sep 30, 2021 | 29.71 Mn |
| Jun 30, 2021 | 29.71 Mn |